Targeted therapeutics for inner ear disorders
Encased in the body's densest bone and shielded by the blood-labyrinth barrier, the inner ear has resisted drug therapy for decades.
Spiral is changing that.
Hearing loss is one of the largest modifiable risk factors for dementia.(Lancet Commission, 2024)
Inner ear diseases have treatable biology but almost no approved drugs
of inner ear disorders stem from inflammation and neurodegeneration
improve hearing but don't treat the underlying conditions
doctors rely on drugs that are not specifically developed or approved for ear treatment
MICS™ and our crosslinked hydrogel
An ophthalmology-style approach to otology. Our drugs are administered at the round window membrane, placed under direct visualization with MICS™ (Minimally Invasive Cochlear System). We are applying this approach to anti-inflammatory, otoprotective, and neuroprotective drugs.
Precision
The single-use MICS Applicator combines a camera, illumination, and an injection cannula to place the hydrogel at the round window membrane under direct visualization.
Residence
The hydrogel stays in the round window niche after a single administration, keeping the drug at the entry point to the inner ear.
Clinic-friendly
Intratympanic administration in the office, under local anesthesia.
A platform-enabled portfolio
Programs advancing across hearing loss and balance disorders.
SPT-2101
Ménière's disease
Dexamethasone otic suspension
2027 US IND clearance
The product
SPT-2101 is an investigational dexamethasone otic suspension that forms a crosslinked hydrogel at the round window membrane. It is placed under direct visualization with MICS™ (Minimally Invasive Cochlear System), by intratympanic administration in the clinic under local anesthesia.
Clinical data
70%of patients had complete resolution of definitive vertigo days at three months after a single administration, the study's primary endpoint. Phase 1b/2a, four sites in Australia, with no serious adverse events.
What's next
US IND clearance in 2027, followed by a registrational trial with a design informed by our analysis of prior Ménière's programs. Sudden hearing loss follows as a second indication in Europe.
Built by category leaders
Our team combines drug-delivery expertise with deep otology and clinical-development experience.
Executive Chairman
Founder & CEO
Independent
Independent
Ferring Ventures SA
Savoir Capital
Catalio Capital
Gund Investment
Independent
News & publications
Spiral Therapeutics Announces $27 Million Series B Financing and Strategic Partnership with Advanced Bionics
SOUTH SAN FRANCISCO, Calif., April 14, 2026 — Spiral Therapeutics, Inc. (“Spiral Therapeutics” or “Spiral”), a clinical-stage company developing novel therapies for inner ear…
Read more
Spiral Therapeutics Announces Successful Completion of the SPT-2101 PHASE 1b/2a Clinical Trial for Meniere’s Disease, Data Presented During the 2024 AAO Annual Meeting
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 — Spiral Therapeutics, Inc. (Spiral), a clinical-stage company focused on developing novel therapies for inner ear disorders, announced the…
Read more
Spiral Therapeutics To Present At The Barany Society Meeting 2024
SOUTH SAN FRANCISCO, Calif., Aug. 21, 2024 — Spiral Therapeutics, Inc. (Spiral), a pharmaceutical company committed to developing advanced treatments for balance disorders and hearing loss,…
Read more